OBJECTIVE: To investigate whether sphericity volume index (SVI), an indicator of left ventricular (LV) remodelling, predicts incident cardiovascular events (coronary heart disease, CHD; all cardiovascular disease, CVD; heart failure, HF; atrial fibrillation, AF) over 10 years of follow-up in a multiethnic population (Multi-Ethnic Study of Atherosclerosis). METHODS: 5004 participants free of known CVD had magnetic resonance imaging (MRI) in 2000-2002. Cine images were analysed to compute, [Formula: see text] equivalent to LV volume/volume of sphere with length of LV as the diameter. The highest (greatest sphericity) and lowest (lowest sphericity) quintiles of SVI were compared against the reference group (2-4 quintiles combined). Risk-factor adjusted hazard's ratio (HR) from Cox regression assessed the predictive performance of SVI at end-diastole (ED) and end-systole (ES) to predict incident outcomes over 10 years in retrospective interpretation of prospective data. RESULTS: At baseline, participants were aged 61±10 years; 52% men and 39%/13%/26%/22% Cauc/Chinese/Afr-Amer/Hispanic. Low sphericity was associated with higher Framingham CVD risk, greater coronary calcium score and higher N-terminal pro-brain natriuretic peptide (NT-proBNP); while increased sphericity was associated with higher NT-proBNP and lower ejection fraction. Low sphericity predicted incident CHD (HR: 1.48, 1.55-2.59 at ED) and CVD (HR: 1.82, 1.47-2.27 at ED). However, both low (HR: 1.81, 1.20-2.73 at ES) and high (HR: 2.21, 1.41-3.46 at ES) sphericity predicted incident HF. High sphericity also predicted AF. CONCLUSIONS: In a multiethnic population free of CVD at baseline, lowest sphericity was a predictor of incident CHD, CVD and HF over a 10-year follow-up period. Extreme sphericity was a strong predictor of incident HF and AF. SVI improved risk prediction models beyond established risk factors only for HF, but not for all CVD or CHD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To investigate whether sphericity volume index (SVI), an indicator of left ventricular (LV) remodelling, predicts incident cardiovascular events (coronary heart disease, CHD; all cardiovascular disease, CVD; heart failure, HF; atrial fibrillation, AF) over 10 years of follow-up in a multiethnic population (Multi-Ethnic Study of Atherosclerosis). METHODS: 5004 participants free of known CVD had magnetic resonance imaging (MRI) in 2000-2002. Cine images were analysed to compute, [Formula: see text] equivalent to LV volume/volume of sphere with length of LV as the diameter. The highest (greatest sphericity) and lowest (lowest sphericity) quintiles of SVI were compared against the reference group (2-4 quintiles combined). Risk-factor adjusted hazard's ratio (HR) from Cox regression assessed the predictive performance of SVI at end-diastole (ED) and end-systole (ES) to predict incident outcomes over 10 years in retrospective interpretation of prospective data. RESULTS: At baseline, participants were aged 61±10 years; 52% men and 39%/13%/26%/22% Cauc/Chinese/Afr-Amer/Hispanic. Low sphericity was associated with higher Framingham CVD risk, greater coronary calcium score and higher N-terminal pro-brain natriuretic peptide (NT-proBNP); while increased sphericity was associated with higher NT-proBNP and lower ejection fraction. Low sphericity predicted incident CHD (HR: 1.48, 1.55-2.59 at ED) and CVD (HR: 1.82, 1.47-2.27 at ED). However, both low (HR: 1.81, 1.20-2.73 at ES) and high (HR: 2.21, 1.41-3.46 at ES) sphericity predicted incident HF. High sphericity also predicted AF. CONCLUSIONS: In a multiethnic population free of CVD at baseline, lowest sphericity was a predictor of incident CHD, CVD and HF over a 10-year follow-up period. Extreme sphericity was a strong predictor of incident HF and AF. SVI improved risk prediction models beyond established risk factors only for HF, but not for all CVD or CHD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Surya P Bhatt; Gonzalo Vegas-Sánchez-Ferrero; Farbod N Rahaghi; Erick S MacLean; German Gonzalez-Serrano; Carolyn E Come; Gregory L Kinney; John E Hokanson; Matthew J Budoff; Michael J Cuttica; J Michael Wells; Raúl San José Estépar; George R Washko Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: Kathleen Gilbert; Nickolas Forsch; Sanjeet Hegde; Charlene Mauger; Jeffrey H Omens; James C Perry; Beau Pontré; Avan Suinesiaputra; Alistair A Young; Andrew D McCulloch Journal: J Cardiovasc Transl Res Date: 2018-01-02 Impact factor: 4.132
Authors: Nickolas Forsch; Sachin Govil; James C Perry; Sanjeet Hegde; Alistair A Young; Jeffrey H Omens; Andrew D McCulloch Journal: J Comput Sci Date: 2020-09-19
Authors: Kasra Moazzami; Mohammad Reza Ostovaneh; Bharath Ambale Venkatesh; Mohammadali Habibi; Kihei Yoneyama; Colin Wu; Kiang Liu; Isabel Pimenta; Annette Fitzpatrick; Steven Shea; Robyn L McClelland; Susan Heckbert; Rebecca F Gottesman; David A Bluemke; Timothy M Hughes; João A C Lima Journal: Hypertension Date: 2018-01-29 Impact factor: 10.190
Authors: Chike C Nwabuo; Henrique T Moreira; Henrique D Vasconcellos; Nathan Mewton; Anders Opdahl; Kofo O Ogunyankin; Bharath Ambale-Venkatesh; Pamela J Schreiner; Anderson A C Armstrong; Cora E Lewis; David R Jacobs; Donald Lloyd-Jones; Samuel S Gidding; João A C Lima Journal: Eur Heart J Cardiovasc Imaging Date: 2019-05-01 Impact factor: 6.875
Authors: Camila M Urzua Fresno; Luciano Folador; Tamar Shalmon; Faisal Mhd Dib Hamad; Sheldon M Singh; Gauri R Karur; Nigel S Tan; Iqwal Mangat; Anish Kirpalani; Binita Riya Chacko; Laura Jimenez-Juan; Andrew T Yan; Djeven P Deva Journal: J Cardiovasc Magn Reson Date: 2021-06-10 Impact factor: 5.364